Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
The TBVPX-113 Study Team
Internal Medicine
Infectious Diseases
Research output
:
Contribution to journal
›
Article
›
peer-review
136
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
Agonist
100%
Immune Response
100%
TLR4
100%
Adjuvant
100%
BCG Vaccine
100%
Mycobacterium Bovis BCG
66%
Normal Human
33%
Cytokine
33%
T-Helper Cell
33%
Monospecific Antibody
33%
Vaccination Policy
33%
Vaccine Efficacy
33%
Immunoglobulin G3
33%
Immunoglobulin G1
33%
Titer
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adjuvant
100%
Toll Like Receptor 4
100%
BCG Vaccine
100%
Mycobacterium Bovis BCG
66%
Clinical Trial
33%
Cytokine
33%
Normal Human
33%
Vaccination Policy
33%
Fusion Protein
33%
Antibodies
33%
Immunoglobulin G3
33%
Immunoglobulin G1
33%
Keyphrases
ID93
100%
Tuberculosis Vaccine
100%